The company is developing prenatal screening for chromosomal defects by a simple maternal blood test. Using MPT’s proprietary Foetal-MpsSep TM column, the foetal MPs are isolated from the mother’s blood and subjected to analysis. MPT’s product will be clinically validated for trisomy 21 and will be expanded to trisomy 18 and 13 as well as other foetal chromosome abnormalities.
The company demonstrated the first proof of concept of the technology while taking a specific disease such as the “Down Syndrome” defect and compares the results against the amniotic fluid test. Within two years the company will have a full blood test kit which could replace the amniotic fluid test in several specific genetic diseases.